Reduced-Dose Chemotherapy Followed By Blinatumomab As Induction Therapy in Treatment of Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia - Interim Results from a Multicenter, Single-Arm, Phase 2 Study

被引：0

作者：

Lu, Jing ^{[1
]}

Wang, Ying ^{[2
]}

Qiu, Huiying ^{[3
]}

Zhou, Xin ^{[4
]}

Lu, Xuzhang ^{[5
]}

Miao, Miao ^{[6
]}

Gu, Bin ^{[1
]}

Hu, Xiaohui ^{[1
]}

Wu, Depei ^{[6
]}

Chen, Suning ^{[1
]}

机构：

[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis,Dept Hematol, Suzhou, Peoples R China

[2] Soochow Univ, Affiliated Hosp 1, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Suzhou, Peoples R China

[3] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol,Natl Clin Res Ctr Hematol Di, Dept Hematol,Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China

[4] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Hematol, Wuxi, Jiangsu, Peoples R China

[5] Nanjing Med Univ, Affiliated Changzhou Hosp 2, Dept Hematol, Changzhou, Jiangsu, Peoples R China

[6] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174831

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)
Martinelli, Giovanni
Dombret, Herve
Chevallier, Patrice
Ottmann, Oliver G.
Goekbuget, Nicola
Topp, Max S.
Fielding, Adele K.
Sterling, Lulu Ren
Benjamin, Jonathan
Stein, Anthony Selwyn
BLOOD, 2015, 126 (23)
[22] BUDGET IMPACT ANALYSIS COMPARING BLINATUMOMAB IN THE TREATMENT OF ADULTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) WITH FLAG-IDA AND HYPER CVAD
Naranjo, M.
Alva, M. E.
Munoz, I
VALUE IN HEALTH, 2017, 20 (09) : A549 - A549
[23] Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Gore, Lia
Locatelli, Franco
Zugmaier, Gerhard
Zwaan, Christian M.
Bhojwani, Deepa
Handgretinger, Rupert
Bader, Peter
O'Brien, Maureen M.
Trippett, Tanya M.
Brethon, Benoit
Rizzari, Carmelo
DuBois, Steven G.
Schlegel, Paul Gerhardt
Barnette, Phillip
Messina, Chiara
Hu, Kuolung
Mergen, Noemi
Fischer, Anja
Whitlock, James
von Stackelberg, Arend
BLOOD, 2014, 124 (21)
[24] Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study
Fleming, Shaun
Reynolds, John
Bajel, Ashish
Venn, Nicola
Kwan, John
Moore, John
Yeung, David T.
Pati, Nalini
Leahy, Michael F.
Nkyekyer, Joanna
Verner, Emma
Berkahn, Leanne
Sutton, Rosemary
Wei, Andrew H.
Greenwood, Matthew
BLOOD, 2021, 138
[25] Efficacy and safety blinatumomab in chinese adults with Ph-negative relapsed/refractory B-cell Precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study
Zhou, Hongsheng
Yin, Qingsong
Jin, Jie
Liu, Ting
Cai, Zhen
Jiang, Bin
Li, Dengju
Sun, Zimin
Li, Yan
He, Yanjuan
Ma, Liping
Gao, Sujun
Hu, Jianda
He, Aili
Du, Xin
Liu, Daihong
Zhang, Xiaohong
Ke, Xiaoyan
Zhuang, Junling
Han, Yue
Wang, Xiaoqin
Chen, Yuqi
Gordon, Paul
Yu, Dong
Zugmaier, Gerhard
Wang, Jianxiang
HEMATOLOGY, 2022, 27 (01) : 917 - 927
[26] Fractionated Inotuzumab Ozogamicin Combined with LowIntensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study
Chevallier, Patrice
Leguay, Thibault
Doubek, Michael
Huguet, Francoise
Salek, Cyril
Cabannes, Aurelie
Wartiovaara-Kautto, Ulla
Saillard, Colombe
Raffoux, Emmanuel
Cluzeau, Thomas
Lepretre, Stephane
Balsat, Marie
Berceanu, Anna
Boissel, Nicolas
Clappier, Emmanuelle
Morisset, Laure
Gardin, Claude
Dombret, Herve
Rousselot, Philippe
BLOOD, 2021, 138
[27] Chemotherapy-Sparing Induction Followed By Consolidation and Maintenance with Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Primary Endpoint Results from the Blissphall Study
Geyer, Mark Blaine
Mascarenhas, John
Smith, Marissa
Pascual, Shakira
Shah, Anmol
Silvestrone, Michael R.
Czaplinska, Tina
Johnson, Kathryn
Thompson, Meghan C.
Park, Jae H.
BLOOD, 2023, 142
[28] Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study (vol 35, pg 1795, 2017)
Martinelli
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (24) : 2856 - 2856
[29] Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia
Short, Nicholas J.
Jabbour, Elias
Jamison, Trevor
Paul, Shilpa
Cuglievan, Branko
McCall, David
Gibson, Amber
Jain, Nitin
Haddad, Fadi G.
Nasr, Lewis F.
Marx, Kayleigh R.
Rausch, Caitlin
Savoy, J. Michael
Garris, Rebecca
Ravandi, Farhad
Kantarjian, Hagop
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (04): : e168 - e173
[30] Bortezomib and Rituximab in Newly Diagnosed Adolescent and Adult CD20-Positive Philadelphia (Ph) Negative Precursor B-Cell Acute Lymphoblastic Leukemia: A Phase II Study
Goli, Vasu Babu
Jain, Hasmukh
Tembhare, Prashant
Shetty, Dhanlaxmi Lalit
Bonda, Avinash
Nayak, Lingaraj
Patkar, Nikhil
Subramanian, Papagudi Ganesan
Sengar, Manju
BLOOD, 2020, 136

← 1 2 3 4 5 →